9
Participants
Start Date
July 7, 2021
Primary Completion Date
July 28, 2023
Study Completion Date
July 28, 2023
JNJ-67896049
Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
Instituto Cardiovascular de Buenos Aires, Ciudad Autonoma Buenos Aires
King Faisal Specialist Hospital & Research Center, Riyadh
DRK Kliniken Westend, Berlin
Gachon University Gil Medical Center, Incheon
AnMed Health, Anderson
Chungnam National University Hospital, Daejeon
CHU Grenoble, La Tronche
Institut Jantung Negara, Kuala Lumpur
Universitatsklinikum Bonn, Bonn
Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz
UT Southwestern, Dallas
University Of California San Diego, La Jolla
Cleveland Clinic Abu Dhabi, Abu Dhabi
National Medical Research Center of Cardiology of MoH of Russian Federation, Moscow
National Heart Centre (NHC) Singapore, Singapore
Federal State Budgetary Institution, Saint Petersburg
Tan Tock Seng Hospital, Singapore
Rabin Medical Center Beilinson Campus, Petah Tikva
Hospital Italiano de Buenos Aires, Caba
Sanatorio Ramon Cereijo, Caba
Associacao Hospitalar Moinhos de Vento, Porto Alegre
Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre
SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo, São Paulo
Hospital Das Clinicas Da Faculdade De Medicina Da USP, São Paulo
Grantham Hospital, Hong Kong
Queen Mary Hospital University of Hong Kong, Hong Kong
Hadassah Medical Center, Jerusalem
VUMC Amsterdam, Amsterdam
Radboud Umcn, Nijmegen
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Golden Jubilee National Hospital, Glasgow
Royal Free Hospital, Hampstead
Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield
Lead Sponsor
Actelion
INDUSTRY